Although promising, the observations from this in vitro study on four breast cancer cell lines remain to be confirmed in in vivo models to corroborate the notion of targeting LDHC to improve clinical outcome of LDHChigh breast cancer patients with poor prognosis, who may benefit from treatment with DNA damage response targeted therapy using DNA damage inducers or PARPi, which is currently only prescribed to BRCA‐mutant patients who constitute a mere 9–15% of TNBCs [70]. The gene discussed is LDHC; the disease is breast cancer.